# eli lilly (blogs) — RSS Amplifier Recent posts from the 9 feeds in the RSS Amplifier directory that cover eli lilly. Page: Feed: --- ## [Metabolic stability: The defining challenge for multifunctional peptides](https://www.drugdiscoverytrends.com/metabolic-stability-the-defining-challenge-for-multifunctional-peptides/) _2026-08-20 · Dr. Hanlin Tao, Haijuan Liu · Drug Discovery and Development_ The demand for peptide therapeutics has grown rapidly in recent years, as the success of GLP-1 drugs has catapulted them to the forefront of developers’ and sponsors’ minds. Although peptides still represent a relatively small share of FDA-approved therapeutics, they offer distinct advantages in treating diseases where small-molecule drugs or therapeutic antibodies fall short. The… The post… ## [As 59% fewer pharma companies cut staff in Q2 in 2026, job postings rise 15%](https://www.drugdiscoverytrends.com/as-59-fewer-pharma-companies-cut-staff-in-q2-in-2026-job-postings-rise-15/) _2026-08-20 · Brian Buntz · Drug Discovery and Development_ 2022 was a big year for layoffs in biopharma. So were the next three. Novartis, for instance, outlined plans to cut up to 8,000 jobs in 2022, after pharmaceutical industry job cuts jumped 280% in 2021. Biogen followed in 2023 with a “Fit for Growth” program that put roughly 1,000 roles on the block. Bristol… The post As 59% fewer pharma companies cut staff in Q2 in 2026, job postings rise 15%… ## [2026 IPO stock tracker: How newly public biotechs are performing](https://www.biospace.com/business/2026-ipo-stock-tracker-how-biotechs-new-to-public-markets-are-performing) _2026-08-19 · Gabrielle Masson · Biopharma Mergers & Acquisitions_ BioSpace is launching an IPO dashboard to help the industry keep tabs on U.S. biotechs that have taken the public plunge in 2026. ## [Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more](https://www.biospace.com/fda/amylyxs-redemption-story-summits-survival-woes-definiums-anxiety-win-more) _2026-08-19 · Jef Akst · Podcasts_ Amylyx shares good news for its investigational GLP-1 blocker; Definium announces positive data for its LSD-based therapy in anxiety; Summit/Akeso’s ivonescimab shows degrading survival benefits; patients treated with Neurocrine’s Prader-Willi drug experience serious adverse events; and Eli Lilly cracks down on the black market for next-gen obesity asset retatrutide. ## [How Sheba Medical Center became OpenAI’s first international hospital partner](https://www.drugdiscoverytrends.com/how-sheba-medical-center-became-openais-first-international-hospital-partner/) _2026-08-18 · Brian Buntz · Drug Discovery and Development_ OpenAI’s first international hospital partnership is taking shape at a giant medical center where English is not the default language and where the electronic health record does not come from Epic, the dominant U.S. EHR vendor. That institution is Sheba Medical Center, the Israel-based medical center with its own 50-plus-person AI Center within ARC, its… The post How Sheba Medical Center became… ## [FDA issues final PDUFA meeting guidance, expands use of written responses](https://www.drugdiscoverytrends.com/fda-issues-final-pdufa-meeting-guidance-expands-use-of-written-responses/) _2026-08-18 · Julia Rock-Torcivia · Drug Discovery and Development_ The FDA has finalized new guidelines for meetings between the FDA and sponsors or applicants relating to the development and review of drugs or biological products under the Prescription Drug User Fee Act (PDUFA). The FDA first published the draft guidance on Sept. 22, 2023, when it collected public comment on the guidelines. The final guidelines contain several changes from the draft, including… ## [Sandoz inks $322M Henlius deal for rights to as many as 10 biosimilars](https://www.biospace.com/drug-delivery/sandoz-inks-322m-henlius-deal-for-rights-to-as-many-as-10-biosimilars) _2026-08-18 · Nick Paul Taylor · Biopharma Mergers & Acquisitions_ The initial batch of biosimilars includes copies of Amgen, Eli Lilly and GSK drugs that collectively generate billions of dollars in annual revenues. ## [LEO adds to dermatology portfolio with $435M deal for late-stage rare disease drug](https://www.biospace.com/business/leo-adds-to-dermatology-portfolio-with-435m-deal-for-late-stage-rare-disease-drug) _2026-08-18 · Annalee Armstrong · Biopharma Mergers & Acquisitions_ This is the third recent acquisition conducted by Denmark’s LEO Pharma in medical dermatology, a portfolio that marked 12% growth in the first half of the year. ## [Rebounding biotech funds expected to spur CDMO growth within year](https://www.biospace.com/business/rebounding-biotech-funds-expected-to-spur-cdmo-growth-within-year) _2026-08-18 · Nick Paul Taylor · Biopharma Mergers & Acquisitions_ With demand for pharma services historically lagging changes in biotech funding, analysts expect CDMOs to experience an uptick in activity in late 2026 or early 2027. ## [Gilead and Nucleai probe why target-positive tumors can still resist ADCs](https://www.drugdiscoverytrends.com/gilead-and-nucleai-probe-why-target-positive-tumors-can-still-resist-adcs/) _2026-08-18 · Brian Buntz · Drug Discovery and Development_ Antibody-drug conjugates (ADCs) have emerged as one of the busiest and most crowded niches within oncology, given their potential to use an antibody to ferry a potent cytotoxic payload toward tumor cells. The class now spans about 15 FDA-approved products, and the segment is growing steadily. Evaluate Pharma projects the ADC category will reach $57… The post Gilead and Nucleai probe why… ## [Earn crypto for idle GPUs (Sponsored)](https://crawlproof.com/a/AuL4I85u8sJU) _2026-08-18 · **Sponsored**_ Run one CLI, host Qwen/Llama/Mistral, and earn BTC, ETH, SOL, or USDC ## [Schrödinger-BMS collaboration centers on Bunsen for trillion-scale computational drug discovery](https://www.drugdiscoverytrends.com/schrodinger-bms-collaboration-centers-on-bunsen-for-trillion-scale-computational-drug-discovery/) _2026-08-17 · Brian Buntz · Drug Discovery and Development_ The 1990-founded scientific software firm Schrödinger recently announced a strategic collaboration and software agreement with Bristol Myers Squibb (BMS) built around Bunsen, Schrödinger’s newly announced agentic AI co-scientist. While the term “AI co-scientist” can have varying definitions, Schrödinger is positioning Bunsen as a sort of execution engine for computational chemistry, including… ## [🔬 Latest pharma industry updates 👇](https://weeklybiopharmaupdates.substack.com/p/latest-pharma-industry-updates-afd) _2026-08-16 · Nicolas Schmitz · 🔬 Latest Pharma Industry Updates_ 🤝 Jazz Pharmaceuticals will acquire Actio Biosciences, Inc. for up to $1.3B, adding a rare epilepsy drug and expanding its neuroscience pipeline. ## [The 50 best-funded biotech companies of 2026](https://www.drugdiscoverytrends.com/the-50-best-funded-biotech-companies-of-2026/) _2026-08-13 · Brian Buntz · Drug Discovery and Development_ By one measure, Alphabet-controlled Isomorphic Labs would tower over every company on this list. The AI drug discovery company has raised $2.7 billion in external financing, including a $2.1 billion Series B announced in May. Its corporate structure, however, puts it outside our definition of an independent biotech startup: Alphabet still controls at least 75%… The post The 50 best-funded biotech… ## [Bristol Myers Squibb to build new plant in Houston](https://www.pharmaceuticalprocessingworld.com/bristol-myers-squibb-to-build-new-plant-in-houston/) _2026-08-13 · Julia Rock Torcivia · Pharmaceutical Processing World_ Bristol Myers Squibb (NYSE: BMY) announced it has selected Houston as the site for a new 600,000-square-foot multi-modal manufacturing campus, representing an approximately $2.3 billion investment. The campus, at Generation Park in Houston, will create nearly 500 skilled jobs, the company said. The campus’ multi-modal capabilities will allow BMS to manufacture multiple types of medicines – such… ## [New cell imaging method reveals hidden enzyme activity](https://www.drugdiscoverytrends.com/new-cell-imaging-method-reveals-hidden-enzyme-activity/) _2026-08-13 · Julia Rock-Torcivia · Drug Discovery and Development_ Negative biosensors have often been unusable because, as the sensors lose signal when activity is detected, regions of high enzyme activity can look identical to regions with no activity. Researchers at the University of Illinois Chicago have solved this problem with a new cell imaging method that allows scientists to see previously hidden enzyme activities by flipping the optical readout of… The… ## [HHS seeks nominees for vaccine advisory panel with $757K estimated annual cost after almost two years without a meeting](https://www.drugdiscoverytrends.com/hhs-seeks-nominees-for-vaccine-advisory-panel-with-757k-estimated-annual-cost-after-almost-two-years-without-a-meeting/) _2026-08-13 · Julia Rock-Torcivia · Drug Discovery and Development_ The Department of Health and Human Services (HHS) is soliciting nominations for appointment to the National Vaccine Advisory Committee (NVAC), the agency said in a notice published Wednesday. A renewed NVAC charter filed in July estimates the committee’s annual operating cost at $756,918 and calls for staff support equivalent to two full-time employees. The committee has not met since September… ## [How computer vision can improve defect detection and traceability in pharma inspection](https://www.pharmaceuticalprocessingworld.com/how-computer-vision-can-improve-defect-detection-and-traceability-in-pharma-inspection/) _2026-08-13 · Lantern Med Digital (LMD) · Pharmaceutical Processing World_ Pharmaceutical manufacturing depends on repeatable inspection. A tablet with a crack, chip, stain, discoloration or other visible anomaly can signal a problem that deserves attention before product moves further downstream. Human inspection remains valuable, but it is inherently variable and difficult to scale consistently across long runs, multiple products and changing operators. Computer vision… ## [Zealand sells milestone, royalty rights to rare blood cancer asset for up to $100M](https://www.biospace.com/deals/zealand-sells-milestone-royalty-rights-to-rare-blood-cancer-asset-for-up-to-100m) _2026-08-13 · Tristan Manalac · Biopharma Mergers & Acquisitions_ The terms of the agreement with Royalty Pharma suggest the market potential of Zealand Pharma’s polycythemia vera drug candidate may be undervalued, according to Jefferies analysts. ## [Bankrupt Sangamo offloads assets to Lilly, PTC in $161M sale](https://www.biospace.com/deals/bankrupt-sangamo-offloads-assets-to-lilly-ptc-in-161m-sale) _2026-08-13 · Tristan Manalac · Biopharma Mergers & Acquisitions_ PTC Therapeutics emerged as the winning bidder over Astellas for Sangamo Therapeutics’ Fabry disease gene therapy, while Eli Lilly is purchasing the biotech’s prion disease program and several platforms. ## [Novo Nordisk’s ziltivekimab misses Phase 3 primary endpoint](https://www.drugdiscoverytrends.com/novo-nordisks-ziltivekimab-misses-phase-3-primary-endpoint/) _2026-08-12 · Julia Rock-Torcivia · Drug Discovery and Development_ Novo Nordisk’s ziltivekimab, an investigational human monoclonal antibody that targets the IL-6 ligand, a pro-inflammatory cytokine, to reduce cardiovascular inflammation, did not reduce the risk of major adverse cardiovascular events (MACE) in a Phase 3 trial. “Although ziltivekimab produced the expected biological effect, this did not result in MACE benefits in this population,” Martin Holst… ## [Countdown to Getting Paid (Sponsored)](https://crawlproof.com/a/2Rb5Sl6cWygC) _2026-08-12 · **Sponsored**_ Create a shareable wallet timer — deposits buy back time and pay debt down ## [Sentynl bets up to $475M in licensing deal for Mereo’s rare lung disease asset](https://www.biospace.com/deals/sentynl-bets-up-to-475m-in-licensing-deal-for-mereos-rare-lung-disease-asset) _2026-08-12 · Tristan Manalac · Biopharma Mergers & Acquisitions_ Mereo BioPharma’s asset, dubbed alvelestat, is set to enter Phase 3 development for AATD-LD in 2027. ## [Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight](https://www.biospace.com/fda/replimune-finally-wins-approval-q2-earnings-wrap-up-psychedelics-stay-in-spotlight) _2026-08-12 · Jef Akst · Podcasts_ After two rejections, Replimune has made it across the regulatory finish line with its advanced melanoma therapy. Meanwhile, the last of the major pharmas, including Eli Lilly and Novo Nordisk, reported second quarter earnings, and psychedelics made headlines once again. ## [After billions in deals, Insilico CEO promises: ‘You haven't seen anything yet’](https://www.biospace.com/business/after-billions-in-deals-insilico-ceo-promises-you-havent-seen-anything-yet) _2026-08-11 · Annalee Armstrong · Biopharma Mergers & Acquisitions_ Insilico Medicine CEO Alex Zhavoronkov’s mad dash across the BIO International Convention in June attracted plenty of eyes. But the executive would prefer industry watchers gawk at the billions of dollars’ worth of deals his company has struck. ## [Jazz commits up to $1.3B to buy Actio, bolster epilepsy pipeline](https://www.biospace.com/deals/jazz-commits-up-to-1-3b-to-buy-actio-bolster-epilepsy-pipeline) _2026-08-10 · Gabrielle Masson · Biopharma Mergers & Acquisitions_ Jazz Pharmaceuticals is reaching into its wallet once again, this time buying Actio Biosciences and an experimental therapy for KCNT1+ epilepsy, a form of the disease with no FDA-approved treatments. ## [AstraZeneca partners with CSPC to build Chinese biologics manufacturing plant](https://www.biospace.com/drug-delivery/astrazeneca-partners-with-cspc-to-build-chinese-biologics-manufacturing-plant) _2026-08-10 · Nick Paul Taylor · Biopharma Mergers & Acquisitions_ News of the joint venture comes months after AstraZeneca vowed to spend $15 billion in China by the end of the decade. ## [Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms](https://www.biospace.com/fda/rumors-of-biggest-pharma-merger-ever-drop-amid-q2-earnings-contentious-fda-adcomms) _2026-08-05 · Jef Akst · Podcasts_ The industry has been abuzz since the weekend when talks of a potential mega-merger between Bristol Myers Squibb and AstraZeneca were reported. Meanwhile, Pfizer, Merck and others release second quarter earnings, with some disclosing pipeline discontinuations and cost-cutting measures. Finally, all eyes turn to the FDA in the wake of heated advisory committee meetings for Capricor Therapeutics and… ## [Codis completes acquisition of Catalent manufacturing plant](https://www.pharmaceuticalprocessingworld.com/codis-completes-acquisition-catalent-plant/) _2026-08-03 · Sean Whooley · Pharmaceutical Processing World_ Codis announced today that it completed its previously announced acquisition of a UK-based manufacturing facility from Catalent. The Haverhill, England-based company agreed to acquire the oral solid dose (OSD) development and manufacturing plant in Nottingham last month. The facility adds OSD development and small-scale manufacturing capabilities to Codis’ offerings, enabling it to offer a single…… ## [Advancing Pressure Protection in Biopharma: How Integrated Bypass Technology Elevates Single-Use Pump Design](https://www.pharmaceuticalprocessingworld.com/advancing-pressure-protection-in-biopharma-how-integrated-bypass-technology-elevates-single-use-pump-design/) _2026-08-01 · Pharmaceutical Processing · Pharmaceutical Processing World_ by Michael Irving, Xylem In pharmaceutical and biopharmaceutical manufacturing, there is zero margin for error when it comes to process integrity and operator safety. Among the many variables that must be tightly controlled, pressure ranks high on the list. Overpressure or vacuum conditions can compromise not only equipment, but also batch sterility, production timelines, and… The post Advancing… ## [Ratio Therapeutics raises $70M to expand manufacturing infrastructure](https://www.pharmaceuticalprocessingworld.com/ratio-therapeutics-raises-70m-expand-manufacturing/) _2026-07-31 · Sean Whooley · Pharmaceutical Processing World_ Ratio Therapeutics announced today that it closed a $70 million Series C financing to support its radiopharmaceutical development and manufacturing. Existing investors Duquesne Family Office and Bristol Myers Squibb participated. New investors Catalio Capital Management, Eli Lilly and Wasatch Group joined as well. Boston-based Ratio plans to use the proceeds to fund its next phase… The post Ratio… ## [Resilience, Lilly invest $750M in pharma, KwikPen manufacturing](https://www.pharmaceuticalprocessingworld.com/resilience-lilly-750m-pharma-kwikpen-manufacturing/) _2026-07-30 · Sean Whooley · Pharmaceutical Processing World_ Resilience announced today that it expanded its strategic partnership with Eli Lilly (NYSE:LLY) to increase medicine production in the U.S. The Cincinnati-based CDMO and the pharmaceutical giant first struck a partnership in 2023. Now, with $750 million invested, the companies are expanding Resilience’s advanced pharmaceutical manufacturing operations in Ohio. Now, Resilience’s production in that… ## [Play Both Sides Of The Lie (Sponsored)](https://crawlproof.com/a/RE1jblLJnP30) _2026-07-30 · **Sponsored**_ Two operatives, one manufactured war — uncover the Complete Truth after both campaigns. ## [Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more](https://www.biospace.com/fda/capricor-and-replimune-prep-for-fda-adcomms-q2-earnings-roll-on-sareptas-new-leader-more) _2026-07-29 · Heather McKenzie · Podcasts_ The FDA published briefing documents ahead of advisory committee meetings for therapies from Capricor Therapeutics and Replimune indicate an uphill battle for the biotechs; GSK and AstraZeneca outline ambitious plans in second quarter presentations; Sarepta taps Michael Severino as its new CEO; and Amgen launches its official defense of Tavneos. ## [OEE is not a hammer, nor is every problem a nail](https://www.pharmaceuticalprocessingworld.com/oee-is-not-a-hammer-nor-is-every-problem-a-nail/) _2026-07-27 · Christian Berg · Pharmaceutical Processing World_ Consider a common scenario: a pharmaceutical manufacturing plant has identified the equipment most critical to the success of its processes and has begun tracking overall equipment effectiveness (OEE) for those assets. Management has set an ambitious OEE metric of 95% for those critical machines, and operators and technicians are collaborating closely to make sure they… The post OEE is not a… ## [BeOne Medicines invests another $300M to expand pharma manufacturing](https://www.pharmaceuticalprocessingworld.com/beone-medicines-invests-more-than-1b-to-expand-pharma-manufacturing/) _2026-07-23 · Sean Whooley · Pharmaceutical Processing World_ BeOne Medicines (Nasdaq:ONC) today announced the investment of $300 million to expand its U.S. manufacturing base. The expansion comes at the company’s flagship clinical and commercial-stage manufacturing and R&D center in Hopewell, New Jersey. It brings BeOne’s total U.S. manufacturing investment to more than $1 billion. BeOne said its latest expansion increases its production capacity… The post… ## [Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2](https://www.biospace.com/drug-development/q2-earnings-underway-fdas-crl-kerfuffle-ipos-full-speed-ahead-in-h2) _2026-07-22 · Jef Akst · Podcasts_ Second quarter earnings continue to roll with Novartis and Roche reporting this week; Eli Lilly’s AtaiBeckley buy for up to $3.8 billion offers clear “validation” for the fledgling psychedelics space; more drama unfolds at FDA as the agency goes back and forth on its policy of publishing complete response letters in real-time; and IPO fever continues. ## [Fujifilm Biotechnologies selected for FDA PreCheck Pilot Program](https://www.pharmaceuticalprocessingworld.com/fujifilm-biotechnologies-selected-fda-precheck-pilot-program-north-carolina/) _2026-07-09 · Skyler Rivera · Pharmaceutical Processing World_ A Fujifilm Biotechnologies’ commercial-scale cell culture manufacturing facility has been selected for the FDA’s PreCheck Pilot Program, the company announced. The CDMO’s Holly Springs, North Carolina, facility was selected as one of seven participants in the program designed to strengthen United States pharmaceutical manufacturing capabilities and accelerate patient access to critical medicines.… ## [Otsuka ICU Medical to invest $500M in IV solutions manufacturing in the US](https://www.pharmaceuticalprocessingworld.com/otsuka-invest-500m-iv-manufacturing-us/) _2026-07-09 · Sean Whooley · Pharmaceutical Processing World_ Otsuka ICU Medical today announced plans to invest more than $500 million to expand its U.S. IV solutions manufacturing in Texas. The companies (Otsuka Pharmaceutical Factory and ICU Medical), which launched this joint venture last year, plan to deliver a new facility and significant upgrades to its existing operations in Austin, Texas. They expect the… The post Otsuka ICU Medical to invest $500M… ## [Allogeneic CD7-Targeted CAR-T Cell (RD13-02) Starts Second Phase-I Clinical Trial](https://cureresearch4type1diabetes.blogspot.com/2026/07/allogeneic-cd7-targeted-car-t-cell-rd13.html) _2026-07-04 · Joshua Levy · Current Research into Cures for Type-1 Diabetes_ RD13-02 uses specially engineered immune cells designed to remove certain immune cells believed to drive the autoimmune attack that damages insulin-producing beta cells. Researchers hope that by removing these harmful immune cells, the immune system may stop attacking the pancreas and allow remaining beta cells to continue working. This is a CAR-T therapy. CAR-T is a genetic engineering technique… ## [SAB-142 From SAb Biotherapeutics Starts a Phase II Trial (SAFEGUARD)](https://cureresearch4type1diabetes.blogspot.com/2026/06/sab-142-from-sab-biotherapeutics-starts.html) _2026-06-16 · Joshua Levy · Current Research into Cures for Type-1 Diabetes_ Back in April, I blogged about a Phase-II study called "Anti-Thymocyte Globulin and Verapamil Start A Phase-2 Clinical Trial" (NCT06455319). I should have included this trial at the same time, since they are closely related, but I didn't so I'm publishing this blog, now. Both studies are testing ATG in honeymooners. The previous study was testing either just ATG or ATG and Verapamil. This study is… ## [Rezpegaldesleukin (or NKTR-358) Starts A Phase-IIΔ Clinical Trial on Honeymooners (RESET T1D)](https://cureresearch4type1diabetes.blogspot.com/2026/06/a-new-clinical-trial-is-testing.html) _2026-06-04 · Joshua Levy · Current Research into Cures for Type-1 Diabetes_ A new clinical trial is testing Rezpegaldesleukin, also known as NKTR-358, or REZPEG, as a potential treatment to slow or stop T1D in honeymooners. Rezpegaldesleukin is a modified form of interleukin-2 (IL-2), which plays a key role in regulating the immune system. The drug is given by subcutaneous injection, similar to an insulin injection, once every two weeks. It has been studied across nine… ## [Phase-I Clinical Trial of Islet Transplantation Into Eye](https://cureresearch4type1diabetes.blogspot.com/2026/05/phase-i-clinical-trial-of-islet.html) _2026-05-14 · Joshua Levy · Current Research into Cures for Type-1 Diabetes_ Pancreatic islet transplantation is an approach designed to restore the body’s ability to produce insulin by transplanting beta cells (insulin-producing cells) from a donor pancreas. I don't consider most of these to be cures, because they require taking immune suppression drugs for the rest of the person's life. For me, that is just trading one disease for another. However, part of the eye (the… ## [Anti-Thymocyte Globulin and Verapamil Start A Phase-2 Clinical Trial](https://cureresearch4type1diabetes.blogspot.com/2026/04/anti-thymocyte-globulin-and-verapamil.html) _2026-05-01 · Joshua Levy · Current Research into Cures for Type-1 Diabetes_ Researchers at the University of Florida are launching a new Phase 2 clinical trial to evaluate a combination therapy for individuals recently diagnosed with type 1 diabetes. This study, titled "Precision Administration of Anti-Thymocyte Globulin (ATG) With or Without Verapamil," aims to preserve the body's ability to produce its own insulin by combining two different types of medication. The… ## [GentiBio starts a Phase-I Clinical Trial on GNTI-122 in Honeymooners (POLARIS)](https://cureresearch4type1diabetes.blogspot.com/2026/04/gentibio-starts-phase-i-clinical-trial.html) _2026-04-09 · Joshua Levy · Current Research into Cures for Type-1 Diabetes_ GentiBio, Inc. is sponsoring a clinical trial known as POLARIS, which aims to evaluate a cell therapy called GNTI-122 in honeymoon adults. It is created specifically for each participant using their own blood cells. GNTI-122 is administered as a single dose. GNTI-122 is designed to modify regulatory T cells - immune cells that help prevent the body from attacking its own tissues. By enhancing the… ## [Results From An Omega-3 and Vitamin D Clinical Trial In People With Long Standing T1D](https://cureresearch4type1diabetes.blogspot.com/2026/02/results-from-omega-3-and-vitamin-d.html) _2026-02-24 · Joshua Levy · Current Research into Cures for Type-1 Diabetes_ Researchers at the University of Miami are exploring whether a combination of two well-known supplements—omega-3 fatty acids and vitamin D—might help preserve insulin production in people with type 1 diabetes. The study, called POSEIDON, is testing whether high doses of these supplements, taken together, can slow the progression of the disease by protecting the remaining beta cells in the… ## [Open Letter: Focus On Hidden Transplanted Beta Cells](https://cureresearch4type1diabetes.blogspot.com/2026/02/open-letter-focus-on-hidden.html) _2026-02-07 · Joshua Levy · Current Research into Cures for Type-1 Diabetes_ An open letter to everyone who cares about research aimed at type 1 diabetes cures. I've been blogging on research aimed at curing type 1 diabetes for almost 20 years, but I've never sent out a message like this before. However, for me, the results from a single person clinical trial of Sana Biotechnology's UP421 treatment should motivate a change in how we all think about research to cure T1D.… ## [SAR442970/Brivekimig Starts a Phase IIΔ Trial In Honeymooners (T1D OBTAIN)](https://cureresearch4type1diabetes.blogspot.com/2026/01/sar442970brivekimig-starts-phase-ii.html) _2026-01-30 · Joshua Levy · Current Research into Cures for Type-1 Diabetes_ The treatment being tested is called Brivekimig (previously SAR442970). It is a type of biologic drug known as a bispecific nanobody. It is a small, engineered protein designed to bind to and block two specific molecules in the immune system simultaneously: Tumor Necrosis Factor-alpha (TNF-alpha) and OX40 Ligand (OX40L). TNF-alpha and OX40L are two of the chemical messengers that help coordinate… ## [Rituximab and Treg Cells Starts a Phase IIΔ Trial In Youth At Risk Of Diabetes](https://cureresearch4type1diabetes.blogspot.com/2026/01/rituximab-and-treg-cells-starts-phase.html) _2026-01-07 · Joshua Levy · Current Research into Cures for Type-1 Diabetes_ A new clinical trial is exploring whether two different immune therapies, used alone or in combination, can delay or prevent the onset of T1D in people who are at high risk, but have not yet been diagnosed with T1D. The study will test a cell-based therapy using a patient's own cells (regulatory T cells) and and a drug called rituximab. It involves drawing a person’s blood, isolating a specific… ## [Fecal Transplantation Starts A Phase-II Trial (FACT-T1D)](https://cureresearch4type1diabetes.blogspot.com/2025/12/fecal-transplantation-starts-phase-ii.html) _2025-12-18 · Joshua Levy · Current Research into Cures for Type-1 Diabetes_ The Fecal Autologous Capsule Transplantation for Type 1 Diabetes Mellitus (FACT-T1D) trial is testing a new approach to treating or curing type 1 diabetes. This method involves the use of encapsulated, freeze-dried, autologous (one's own) fecal matter. The idea is that by altering the gut microbiota, it might be possible to slow down or even halt the destruction of beta cells, which are crucial… ## [CNK-UT009 Cell Therapy Starts A Phase-I Clinical Trial](https://cureresearch4type1diabetes.blogspot.com/2025/12/cnk-ut009-cell-therapy-starts-phase-i.html) _2025-12-05 · Joshua Levy · Current Research into Cures for Type-1 Diabetes_ CNK-UT009, as tested here, is a one-time infusion of living cells designed to modify the immune system’s behavior. The idea behind it is that by reprogramming T cells, it may be possible to suppress the misdirected immune response that causes type 1 diabetes while potentially allowing remaining beta cells to function better. Animal studies suggest that this method could reduce autoimmunity and… ## [IMMUNOSTEM starts a Phase-I Clinical Trial in Honeymooners](https://cureresearch4type1diabetes.blogspot.com/2025/10/immunostem-starts-phase-i-clinical.html) _2025-10-30 · Joshua Levy · Current Research into Cures for Type-1 Diabetes_ IMMUNOSTEM technology refers to using a virus (specifically a lentivirus) to deliver a new gene into cells, which will then produce a specific protein PD-L1 (Programmed Death-Ligand 1). This protein plays a key role in the immune system by telling T-cells not to attack a specific other cell (in this case, beta cells). This is done to the patient's own blood. It is removed, treated in this way, and… ## [Results from a Phase-II Clinical Trial of Baricitinib](https://cureresearch4type1diabetes.blogspot.com/2025/09/results-from-phase-ii-clinical-trial-of.html) _2025-09-27 · Joshua Levy · Current Research into Cures for Type-1 Diabetes_ Baricitinib works by interfering with signaling pathways inside immune cells, to reduce inflammation and lower the immune system. It is part of a class of drugs called Janus kinase (JAK) inhibitors. JAK comes in two forms, JAK1 and JAK2, and Baricitinib targets both of them. Baricitinib is not a new drug; it was first approved by the US Food and Drug Administration (FDA) in 2018. It is taken as a…